Medical

Polisano Pharmaceuticals

In 2019, GRAMPET Group acquired the majority stake in Polisano Pharmaceuticals. Polisano's objective is to expand its operations and become a leading player in Central and South-eastern Europe in the production of oncology drugs. The company's portfolio includes partners from over 35 countries.